JP2006515334A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006515334A5 JP2006515334A5 JP2006500001A JP2006500001A JP2006515334A5 JP 2006515334 A5 JP2006515334 A5 JP 2006515334A5 JP 2006500001 A JP2006500001 A JP 2006500001A JP 2006500001 A JP2006500001 A JP 2006500001A JP 2006515334 A5 JP2006515334 A5 JP 2006515334A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- pyrrolo
- dihydro
- compound
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 28
- -1 nitro, hydroxy Chemical group 0.000 claims 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 5
- 238000006243 chemical reaction Methods 0.000 claims 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000000335 thiazolyl group Chemical group 0.000 claims 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000003172 aldehyde group Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 claims 2
- 101800000414 Corticotropin Proteins 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 102100027467 Pro-opiomelanocortin Human genes 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 239000003638 chemical reducing agent Substances 0.000 claims 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims 2
- 229960000258 corticotropin Drugs 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 239000003488 releasing hormone Substances 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- XGHYLYUXJUMEEF-UHFFFAOYSA-N 1-(4-methoxy-2-methylphenyl)-6-methyl-4-(3-pyrazol-1-ylpyrazol-1-yl)-2,3-dihydropyrrolo[2,3-b]pyridine Chemical compound CC1=CC(OC)=CC=C1N1C(N=C(C)C=C2N3N=C(C=C3)N3N=CC=C3)=C2CC1 XGHYLYUXJUMEEF-UHFFFAOYSA-N 0.000 claims 1
- BISOKIVPXCKTDB-UHFFFAOYSA-N 1-[2,4-bis(trifluoromethyl)phenyl]-6-methyl-4-(3-pyridin-2-ylpyrazol-1-yl)-2,3-dihydropyrrolo[2,3-b]pyridine Chemical compound C12=NC(C)=CC(N3N=C(C=C3)C=3N=CC=CC=3)=C2CCN1C1=CC=C(C(F)(F)F)C=C1C(F)(F)F BISOKIVPXCKTDB-UHFFFAOYSA-N 0.000 claims 1
- XIWHXZSMSYEUAW-UHFFFAOYSA-N 2-[1-[1-(2,4-dimethoxyphenyl)-6-methyl-2,3-dihydropyrrolo[2,3-b]pyridin-4-yl]pyrazol-3-yl]-1,3-thiazole Chemical compound COC1=CC(OC)=CC=C1N1C(N=C(C)C=C2N3N=C(C=C3)C=3SC=CN=3)=C2CC1 XIWHXZSMSYEUAW-UHFFFAOYSA-N 0.000 claims 1
- RDLKNOVFACOIFT-UHFFFAOYSA-N 2-[1-[1-(2-chloro-4-methoxyphenyl)-6-methyl-2,3-dihydropyrrolo[2,3-b]pyridin-4-yl]pyrazol-3-yl]-1,3-thiazole Chemical compound ClC1=CC(OC)=CC=C1N1C(N=C(C)C=C2N3N=C(C=C3)C=3SC=CN=3)=C2CC1 RDLKNOVFACOIFT-UHFFFAOYSA-N 0.000 claims 1
- YTWQZXCSOKIJSD-UHFFFAOYSA-N 2-[1-[1-(4-fluoro-2-methylphenyl)-6-methyl-2,3-dihydropyrrolo[2,3-b]pyridin-4-yl]pyrazol-3-yl]-1,3-thiazole Chemical compound C12=NC(C)=CC(N3N=C(C=C3)C=3SC=CN=3)=C2CCN1C1=CC=C(F)C=C1C YTWQZXCSOKIJSD-UHFFFAOYSA-N 0.000 claims 1
- OWDRGDIMOGRUBC-UHFFFAOYSA-N 2-[1-[1-(4-methoxy-2-methylphenyl)-6-methyl-2,3-dihydropyrrolo[2,3-b]pyridin-4-yl]pyrazol-3-yl]-1,3-thiazole Chemical compound CC1=CC(OC)=CC=C1N1C(N=C(C)C=C2N3N=C(C=C3)C=3SC=CN=3)=C2CC1 OWDRGDIMOGRUBC-UHFFFAOYSA-N 0.000 claims 1
- ZVTDJFCIQSZODD-UHFFFAOYSA-N 2-[1-[1-[2,4-bis(trifluoromethyl)phenyl]-6-methyl-2,3-dihydropyrrolo[2,3-b]pyridin-4-yl]pyrazol-3-yl]-1,3-thiazole Chemical compound C12=NC(C)=CC(N3N=C(C=C3)C=3SC=CN=3)=C2CCN1C1=CC=C(C(F)(F)F)C=C1C(F)(F)F ZVTDJFCIQSZODD-UHFFFAOYSA-N 0.000 claims 1
- IGAANYSOTBNWCB-UHFFFAOYSA-N 2-[1-[1-[2-(difluoromethyl)-4-methoxyphenyl]-6-methyl-2,3-dihydropyrrolo[2,3-b]pyridin-4-yl]pyrazol-3-yl]-1,3-thiazole Chemical compound FC(F)C1=CC(OC)=CC=C1N1C(N=C(C)C=C2N3N=C(C=C3)C=3SC=CN=3)=C2CC1 IGAANYSOTBNWCB-UHFFFAOYSA-N 0.000 claims 1
- JYFKCJUYMDDGNO-UHFFFAOYSA-N 2-[1-[6-methyl-1-[2-methyl-4-(trifluoromethoxy)phenyl]-2,3-dihydropyrrolo[2,3-b]pyridin-4-yl]pyrazol-3-yl]-1,3-thiazole Chemical compound C12=NC(C)=CC(N3N=C(C=C3)C=3SC=CN=3)=C2CCN1C1=CC=C(OC(F)(F)F)C=C1C JYFKCJUYMDDGNO-UHFFFAOYSA-N 0.000 claims 1
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 claims 1
- OGOBINRVCUWLGN-UHFFFAOYSA-N 3-(trifluoromethyl)benzonitrile Chemical compound FC(F)(F)C1=CC=CC(C#N)=C1 OGOBINRVCUWLGN-UHFFFAOYSA-N 0.000 claims 1
- ZSYXANJIHMWGIM-UHFFFAOYSA-N 3-chloro-4-[6-methyl-4-(3-pyrazol-1-ylpyrazol-1-yl)-2,3-dihydropyrrolo[2,3-b]pyridin-1-yl]benzonitrile Chemical compound C12=NC(C)=CC(N3N=C(C=C3)N3N=CC=C3)=C2CCN1C1=CC=C(C#N)C=C1Cl ZSYXANJIHMWGIM-UHFFFAOYSA-N 0.000 claims 1
- ZQUBKLVLPUQWAU-UHFFFAOYSA-N 3-chloro-4-[6-methyl-4-(3-pyridin-2-ylpyrazol-1-yl)-2,3-dihydropyrrolo[2,3-b]pyridin-1-yl]benzonitrile Chemical compound C12=NC(C)=CC(N3N=C(C=C3)C=3N=CC=CC=3)=C2CCN1C1=CC=C(C#N)C=C1Cl ZQUBKLVLPUQWAU-UHFFFAOYSA-N 0.000 claims 1
- SVAFQVGQKNHWEO-UHFFFAOYSA-N 3-chloro-4-[6-methyl-4-[3-(1,3-thiazol-2-yl)pyrazol-1-yl]-2,3-dihydropyrrolo[2,3-b]pyridin-1-yl]benzonitrile Chemical compound C12=NC(C)=CC(N3N=C(C=C3)C=3SC=CN=3)=C2CCN1C1=CC=C(C#N)C=C1Cl SVAFQVGQKNHWEO-UHFFFAOYSA-N 0.000 claims 1
- FWTPDVFXYIDZBG-UHFFFAOYSA-N 3-ethyl-4-[6-methyl-4-[3-(1,3-thiazol-2-yl)pyrazol-1-yl]-2,3-dihydropyrrolo[2,3-b]pyridin-1-yl]benzonitrile Chemical compound CCC1=CC(C#N)=CC=C1N1C(N=C(C)C=C2N3N=C(C=C3)C=3SC=CN=3)=C2CC1 FWTPDVFXYIDZBG-UHFFFAOYSA-N 0.000 claims 1
- XDZKYQACIVBBGK-UHFFFAOYSA-N 3-methyl-4-[6-methyl-4-(3-pyrazol-1-ylpyrazol-1-yl)-2,3-dihydropyrrolo[2,3-b]pyridin-1-yl]benzonitrile Chemical compound C12=NC(C)=CC(N3N=C(C=C3)N3N=CC=C3)=C2CCN1C1=CC=C(C#N)C=C1C XDZKYQACIVBBGK-UHFFFAOYSA-N 0.000 claims 1
- SFXBVWAIBITQFM-UHFFFAOYSA-N 3-methyl-4-[6-methyl-4-(3-pyridin-2-ylpyrazol-1-yl)-2,3-dihydropyrrolo[2,3-b]pyridin-1-yl]benzonitrile Chemical compound C12=NC(C)=CC(N3N=C(C=C3)C=3N=CC=CC=3)=C2CCN1C1=CC=C(C#N)C=C1C SFXBVWAIBITQFM-UHFFFAOYSA-N 0.000 claims 1
- PILQTHJQQVUSEV-UHFFFAOYSA-N 3-methyl-4-[6-methyl-4-[3-(1,3-thiazol-2-yl)pyrazol-1-yl]-2,3-dihydropyrrolo[2,3-b]pyridin-1-yl]benzonitrile Chemical compound C12=NC(C)=CC(N3N=C(C=C3)C=3SC=CN=3)=C2CCN1C1=CC=C(C#N)C=C1C PILQTHJQQVUSEV-UHFFFAOYSA-N 0.000 claims 1
- WLFSOQFAMYMKAQ-UHFFFAOYSA-N 4-[6-methyl-4-(3-pyrazol-1-ylpyrazol-1-yl)-2,3-dihydropyrrolo[2,3-b]pyridin-1-yl]-3-(trifluoromethyl)benzonitrile Chemical compound C12=NC(C)=CC(N3N=C(C=C3)N3N=CC=C3)=C2CCN1C1=CC=C(C#N)C=C1C(F)(F)F WLFSOQFAMYMKAQ-UHFFFAOYSA-N 0.000 claims 1
- YWYYPOUTPUGLCR-UHFFFAOYSA-N 4-[6-methyl-4-[3-(1,3-thiazol-2-yl)pyrazol-1-yl]-2,3-dihydropyrrolo[2,3-b]pyridin-1-yl]-3-(trifluoromethoxy)benzonitrile Chemical compound C12=NC(C)=CC(N3N=C(C=C3)C=3SC=CN=3)=C2CCN1C1=CC=C(C#N)C=C1OC(F)(F)F YWYYPOUTPUGLCR-UHFFFAOYSA-N 0.000 claims 1
- IUDHIXABFWMKSO-UHFFFAOYSA-N 4-[6-methyl-4-[3-(1,3-thiazol-2-yl)pyrazol-1-yl]-2,3-dihydropyrrolo[2,3-b]pyridin-1-yl]-3-(trifluoromethyl)benzonitrile Chemical compound C12=NC(C)=CC(N3N=C(C=C3)C=3SC=CN=3)=C2CCN1C1=CC=C(C#N)C=C1C(F)(F)F IUDHIXABFWMKSO-UHFFFAOYSA-N 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 1
- 238000007125 Buchwald synthesis reaction Methods 0.000 claims 1
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- 208000020401 Depressive disease Diseases 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 238000007239 Wittig reaction Methods 0.000 claims 1
- 238000005903 acid hydrolysis reaction Methods 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 238000010511 deprotection reaction Methods 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 150000002084 enol ethers Chemical class 0.000 claims 1
- 125000004185 ester group Chemical group 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 238000003402 intramolecular cyclocondensation reaction Methods 0.000 claims 1
- IEATWGSHWKJCRU-UHFFFAOYSA-N n,n,4-trimethyl-5-[6-methyl-4-[3-(1,3-thiazol-2-yl)pyrazol-1-yl]-2,3-dihydropyrrolo[2,3-b]pyridin-1-yl]pyridin-2-amine Chemical compound C1=NC(N(C)C)=CC(C)=C1N1C(N=C(C)C=C2N3N=C(C=C3)C=3SC=CN=3)=C2CC1 IEATWGSHWKJCRU-UHFFFAOYSA-N 0.000 claims 1
- 239000007800 oxidant agent Substances 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 150000003222 pyridines Chemical class 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000004001 thioalkyl group Chemical group 0.000 claims 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44043203P | 2003-01-16 | 2003-01-16 | |
| PCT/EP2004/000409 WO2004062665A1 (en) | 2003-01-16 | 2004-01-14 | Heteroaryl- substituted pyrrolo` 2, 3- b! pyridine derivatives as crf receptor antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006515334A JP2006515334A (ja) | 2006-05-25 |
| JP2006515334A5 true JP2006515334A5 (https=) | 2007-03-01 |
Family
ID=32713552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006500001A Pending JP2006515334A (ja) | 2003-01-16 | 2004-01-14 | ＣＲＦ受容体アンタゴニストとしてのヘテロアリール置換ピロロ［２，３−ｂ］ピリジン誘導体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20070066640A1 (https=) |
| EP (1) | EP1583531B1 (https=) |
| JP (1) | JP2006515334A (https=) |
| AT (1) | ATE359782T1 (https=) |
| DE (1) | DE602004005960T2 (https=) |
| ES (1) | ES2285409T3 (https=) |
| WO (1) | WO2004062665A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0117396D0 (en) | 2001-07-17 | 2001-09-05 | Glaxo Group Ltd | Chemical compounds |
| MXPA05007485A (es) | 2003-01-14 | 2006-01-30 | Arena Pharm Inc | Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia. |
| GB0308208D0 (en) | 2003-04-09 | 2003-05-14 | Glaxo Group Ltd | Chemical compounds |
| AR045047A1 (es) | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
| US7132426B2 (en) | 2003-07-14 | 2006-11-07 | Arena Pharmaceuticals, Inc. | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| CA2550948A1 (en) * | 2003-12-22 | 2005-07-14 | Sb Pharmco Puerto Rico Inc. | Crf receptor antagonists and methods relating thereto |
| US7820654B2 (en) | 2004-09-23 | 2010-10-26 | Dr. Reddy's Laboratories Ltd. | Pyrimidine compounds, process for their preparation and compositions containing them |
| GB0519957D0 (en) * | 2005-09-30 | 2005-11-09 | Sb Pharmco Inc | Chemical compound |
| DE602005014375D1 (de) * | 2004-10-19 | 2009-06-18 | Neurocrine Biosciences Inc | Crf-rezeptor-antagonisten und zugehörige verfahren |
| GB0507198D0 (en) * | 2005-04-08 | 2005-05-18 | Sb Pharmco Inc | Process for preparing bicyclic compounds |
| US8088779B2 (en) * | 2005-09-30 | 2012-01-03 | Smithkline Beecham (Cork) Limited | Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists |
| FR2903985B1 (fr) | 2006-07-24 | 2008-09-05 | Sanofi Aventis Sa | Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique |
| FR2904316B1 (fr) | 2006-07-31 | 2008-09-05 | Sanofi Aventis Sa | Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique. |
| JP2010501567A (ja) | 2006-08-24 | 2010-01-21 | ノバルティス アクチエンゲゼルシャフト | 代謝系、心血管系および他の障害の処置のためのステアロイル−ＣｏＡ不飽和化酵素（ＳＣＤ）阻害剤としての２−（ピラジン−２−イル）−チアゾールおよび２−（１Ｈ−ピラゾール−３−イル）チアゾール誘導体ならびに関連化合物 |
| FR2910473B1 (fr) | 2006-12-26 | 2009-02-13 | Sanofi Aventis Sa | Derives de n-(amino-heteroaryl)-1h-pyrrolopyridine-2- carboxamides, leur preparation et leur application en therapeutique. |
| EP2440204B1 (en) | 2009-06-12 | 2013-12-18 | Bristol-Myers Squibb Company | Nicotinamide compounds useful as kinase modulators |
| PH12013500547A1 (en) | 2010-09-22 | 2013-06-10 | Arena Pharm Inc | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| EP2928471B1 (en) | 2012-12-06 | 2020-10-14 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| MX386419B (es) | 2015-01-06 | 2025-03-18 | Arena Pharm Inc | Metodos de condiciones de tratamiento relacionadas con el receptor s1p1. |
| EP3939965A1 (en) | 2015-06-22 | 2022-01-19 | Arena Pharmaceuticals, Inc. | Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in sipi receptor-associated disorders |
| MA47504A (fr) | 2017-02-16 | 2019-12-25 | Arena Pharm Inc | Composés et méthodes de traitement de l'angiocholite biliaire primitive |
| ES2987794T3 (es) | 2018-06-06 | 2024-11-18 | Arena Pharm Inc | Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW530047B (en) * | 1994-06-08 | 2003-05-01 | Pfizer | Corticotropin releasing factor antagonists |
| US5955613A (en) * | 1995-10-13 | 1999-09-21 | Neurogen Corporation | Certain pyrrolopyridine derivatives; novel CRF1 specific ligands |
| JP2002510687A (ja) * | 1998-04-02 | 2002-04-09 | ニューロゲン コーポレイション | アミノアルキル置換ピロロ［２，３−ｂ］ピリジンおよびピロロ［２，３−ｄ］ピリミジン誘導体：ｃｒｆ１レセプタのモジュレータ |
| HRP20020599A2 (en) * | 2000-01-18 | 2004-08-31 | Pfizer Prod Inc | Corticotropin releasing factor antagonists |
| IL158062A0 (en) * | 2001-04-30 | 2004-03-28 | Glaxo Group Ltd | Fused pyrimidines as antagonists of the corticotropin releasing factor (crf) |
| GB0117396D0 (en) * | 2001-07-17 | 2001-09-05 | Glaxo Group Ltd | Chemical compounds |
-
2004
- 2004-01-14 DE DE602004005960T patent/DE602004005960T2/de not_active Expired - Lifetime
- 2004-01-14 WO PCT/EP2004/000409 patent/WO2004062665A1/en not_active Ceased
- 2004-01-14 ES ES04701955T patent/ES2285409T3/es not_active Expired - Lifetime
- 2004-01-14 EP EP04701955A patent/EP1583531B1/en not_active Expired - Lifetime
- 2004-01-14 AT AT04701955T patent/ATE359782T1/de not_active IP Right Cessation
- 2004-01-14 JP JP2006500001A patent/JP2006515334A/ja active Pending
- 2004-01-14 US US10/542,196 patent/US20070066640A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006515334A5 (https=) | ||
| JP7401482B2 (ja) | コロニー刺激因子－１受容体（ｃｓｆ－１ｒ）阻害剤 | |
| JP7457708B2 (ja) | Ｒｅｔ阻害剤、医薬組成物およびその使用 | |
| US9351973B2 (en) | Pyrazolopyridyl compounds as aldosterone synthase inhibitors | |
| JP4814783B2 (ja) | ピラゾロピリジン誘導体 | |
| JP5833010B2 (ja) | 抗癌剤としてのピラゾロピリジン誘導体 | |
| CA2832996C (en) | Tricyclic triazole compounds and their use as aldosterone synthase inhibitors | |
| US20100010035A1 (en) | Novel Dual Action Receptors Antagonists (Dara) at the Ati and Eta Receptors | |
| JP2004513134A (ja) | Ｈｉｖインテグラーゼ阻害薬として有用なアザ−およびポリアザ−ナフタレニルケトン類 | |
| EP2757882B1 (en) | Imidazopyridyl compounds as aldosterone synthase inhibitors | |
| CA2521929A1 (en) | Condensed n-heterocyclic compounds and their use as crf receptor antagonists | |
| JP2004502760A (ja) | ピラゾール誘導体 | |
| WO2012012478A1 (en) | Aldosterone synthase inhibitors | |
| TWI891812B (zh) | 雙環化合物、包含其的藥物組合物及其應用 | |
| US9567333B2 (en) | Triazolopyridyl compounds as aldosterone synthase inhibitors | |
| US20220081439A1 (en) | Haloallylamine compounds and application thereof | |
| TWI532740B (zh) | ２－胺基－３－（咪唑－２－基）－吡啶－４－酮衍生物、其製備方法及其治療用途 | |
| JP6605624B2 (ja) | 新規なヘテロ環化合物、その製造方法およびこれを含む薬学的組成物 | |
| CN103958511A (zh) | 作为胆固醇酯转移蛋白(CETP)抑制剂用于治疗动脉粥样硬化的5-苄基氨基甲基-6-氨基吡唑并[3,4-b]吡啶衍生物 | |
| CN107849031A (zh) | 用于治疗细菌感染的甘露糖衍生物 | |
| JP2006505625A (ja) | Ｈｉｖ感染症を治療するためのピラゾールアミド | |
| JP2004529969A (ja) | 新規のピリジルメチルアミノピリミジン | |
| JP2008534642A (ja) | 二環式化合物の調製方法 |